The Drug-Induced Respiratory Disease Website
Arrhythmias-Dysrhythmias, including atrial fibrillation (Review at PMID 15582307), ventricular tachycardia/fibrillation See also under torsades de pointe under XIIt
Publications
Management of adverse effects/toxicity of ibrutinib.
Critical reviews in oncology/hematology 2019 Apr;136;56-63 — 2019 Apr — 56-63
Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R, Nohria A
Ibrutinib-Associated Atrial Fibrillation.
JACC. Clinical electrophysiology 2018 Dec;4;1491-1500 — 2018 Dec — 1491-1500
Ibrutinib-related atrial fibrillation: Therapeutic challenges.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019 Jul;25;1258-1260 — 2019 Jul — 1258-1260
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
The New England journal of medicine 2016 Oct 13;375;1457-1467 — 2016 Oct 13 — 1457-1467
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
Blood 2014 Dec 11;124;3829-30 — 2014 Dec 11 — 3829-30
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A,
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
The New England journal of medicine 2014 Jul 17;371;213-23 — 2014 Jul 17 — 213-23